Boston Scientific COO Praises FDA Combo Efforts, Warns of Grueling Process
This article was originally published in The Gray Sheet
Executive Summary
FDA's combination products approval process is effective at offsetting some challenges to developing and marketing drug-device pairings, according to Boston Scientific Chief Operating Officer Paul LaViolette